Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial

被引:82
|
作者
Ahn, Jiyoung [1 ]
Albanes, Demetrius [1 ]
Peters, Ulrike [2 ]
Schatzkin, Arthur [1 ]
Lim, Unhee [1 ]
Freedman, Michal [1 ]
Chatterjee, Nilanjan [1 ]
Andriole, Gerald L. [3 ]
Leitzmann, Michael F. [1 ]
Hayes, Richard B. [1 ]
机构
[1] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[2] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Fred Hutchinson Canc Res Ctr,Canc Prevent Program, Seattle, WA 98195 USA
[3] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA
关键词
D O I
10.1158/1055-9965.EPI-07-0601
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Higher intakes of calcium and dairy products, a major source of dietary calcium, are reported to increase the risk of prostate cancer, potentially due to reductions in circulating vitamin D with increasing calcium intake. We prospectively examined the association of dairy product and calcium intake with prostate cancer risk in 29,509 men, including 1,910 cases, in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. We also evaluated the relation of calcium intake with serum 25-hydroxy-vitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)(2)D], in a Prostate, Lung, Colorectal, and Ovarian Trial substudy (n = 275). Dietary intake was assessed using a food frequency questionnaire. Baseline serum 1,25(OH)2D was determined by RIA. Greater intake of dairy products, particularly low-fat dairy products, was weakly associated with increased risk of prostate cancer [relative risk (RR), 1.12; 95% confidence intervals (CI), 0.97-1.30; P trend = 0.06 for >2.75 versus <= 0.98 servings of total dairy/day; 1.23 (1.07-1.41) for low-fat dairy]. Greater dietary calcium intake was associated with increased risk of prostate cancer (RR, 1.34; 95% CI, 0.93-1.94; P trend = 0.02 for >2,000 versus <1,000 mg/day), but greater supplementary calcium intake was not associated with the risk. Associations of dairy product and dietary calcium intake were evident for nonaggressive disease (RR, 1.20; 95% CI, 0.99-1.46; P trend = 0.01 for dairy products; 1.64, 1.04-2.57; P trend = 0.002 for dietary calcium), but not aggressive disease (RR, 1.02; 95% CI, 0.81-1.28 for dairy products; 0.94, 0.49-1.80 for dietary calcium). Calcium intake was not associated with serum 25-hydroxyvitamin D and 1,25(OH)(2)D concentration. In this large prospective study in a prostate cancer screening trial, greater dietary intake of calcium and dairy products, particularly low-fat types, may be modestly associated with increased risks for nonaggressive prostate cancer, but was unrelated to aggressive disease. Furthermore, we found no relationship between calcium intake and circulating vitamin D.
引用
收藏
页码:2623 / 2630
页数:8
相关论文
共 50 条
  • [31] Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Pinsky, Paul F.
    Black, Amanda
    Parnes, Howard L.
    Grubb, Robert
    Crawford, E. David
    Miller, Anthony
    Reding, Douglas
    Andriole, Gerald
    [J]. CANCER EPIDEMIOLOGY, 2012, 36 (06) : E401 - E406
  • [32] Lung Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Hocking, William G.
    Hu, Ping
    Oken, Martin M.
    Winslow, Stephen D.
    Kvale, Paul A.
    Prorok, Philip C.
    Ragard, Lawrence R.
    Commins, John
    Lynch, David A.
    Andriole, Gerald L.
    Buys, Saundra S.
    Fouad, Mona N.
    Fuhrman, Carl R.
    Isaacs, Claudine
    Yokochi, Lance A.
    Riley, Thomas L.
    Pinsky, Paul F.
    Gohagan, John K.
    Berg, Christine D.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (10) : 722 - 731
  • [33] The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort
    Kawakita, Daisuke
    Lee, Yuan-Chin Amy
    Gren, Lisa H.
    Buys, Saundra S.
    La Vecchia, Carlo
    Hashibe, Mia
    [J]. BRITISH JOURNAL OF CANCER, 2018, 118 (02) : 299 - 306
  • [34] The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort
    Daisuke Kawakita
    Yuan-Chin Amy Lee
    Lisa H Gren
    Saundra S Buys
    Carlo La Vecchia
    Mia Hashibe
    [J]. British Journal of Cancer, 2018, 118 : 299 - 306
  • [35] Dairy products, calcium and prostate cancer risk
    K A Koh
    H D Sesso
    R S Paffenbarger
    I-M Lee
    [J]. British Journal of Cancer, 2006, 95 : 1582 - 1585
  • [36] Calcium, dairy products, and the risk of prostate cancer
    Tavani, A
    Gallus, S
    Franceschi, S
    La Vecchia, C
    [J]. PROSTATE, 2001, 48 (02): : 118 - 121
  • [37] Dairy products, calcium and prostate cancer risk
    Koh, K. A.
    Sesso, H. D.
    Paffenbarger, R. S., Jr.
    Lee, I-M
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (11) : 1582 - 1585
  • [38] Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Pinsk, Paul F.
    Black, Amanda
    Daugherty, Sarah E.
    Hoover, Robert
    Parnes, Howard
    Smith, Zachary L.
    Eggener, Scott
    Andriole, Gerald L.
    Berndt, Sonja, I
    [J]. CANCER, 2019, 125 (17) : 2965 - 2974
  • [39] Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
    Zhong, Guo-Chao
    Peng, Yang
    Wang, Kang
    Wan, Lun
    Wu, You-Qi-Le
    Hao, Fa-Bao
    Hu, Jie-Jun
    Gu, Hai-Tao
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (06) : 1577 - 1586
  • [40] Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Prorok, PC
    Andriole, GL
    Bresalier, RS
    Buys, SS
    Chia, D
    Crawford, ED
    Fogel, R
    Gelmann, EP
    Gilbert, F
    Hasson, MA
    Hayes, RB
    Johnson, CC
    Mandel, JS
    Oberman, A
    O'Brien, B
    Oken, MM
    Rafla, S
    Reding, D
    Rutt, W
    Weissfeld, JL
    Yokochi, L
    Gohagan, JK
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 273S - 309S